Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor

被引：0
|
作者：
Yamakawa, Hiroko [1 ]
Mizutani, Akio [1 ]
Arikawa, Yasuyoshi [1 ]
Ebara, Shunsuke [1 ]
Satoh, Yoshihiko [1 ]
Morishita, Daisuke [1 ]
机构：
[1] Chordia Therapeut Inc, Fujisawa, Kanagawa, Japan
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5485
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
    Liu, Yahong
    Cheng, Ying
    Huang, Gongchao
    Xia, Xiangying
    Wang, Xingkai
    Tian, Hongqi
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [32] Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor
    Caenepeel, Sean
    Karen, Rex
    Belmontes, Brian
    Verlinsky, Alla
    Tan, Hong
    Yang, Yajing
    Chen, Xiaoyue
    Li, Kexue
    Allen, Jennifer
    Wahlstrom, Jan
    Canon, Jude
    Coxon, Angela
    Hughes, Paul
    CANCER RESEARCH, 2020, 80 (16)
  • [33] Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
    Hossain, Md Mehedi
    Khalid, Arfan
    Akhter, Zaheen
    Parveen, Sabra
    Ayaz, Mir Owais
    Bhat, Aadil Qadir
    Badesra, Neetu
    Showket, Farheen
    Dar, Mohmmad Saleem
    Ahmed, Farhan
    Dhiman, Sumit
    Kumar, Mukesh
    Singh, Umed
    Hussain, Razak
    Keshari, Pankaj
    Mustafa, Ghulam
    Nargorta, Amit
    Taneja, Neha
    Gupta, Somesh
    Mir, Riyaz A.
    Kshatri, Aravind Singh
    Nandi, Utpal
    Khan, Nooruddin
    Ramajayan, P.
    Yadav, Govind
    Ahmed, Zabeer
    Singh, Parvinder Pal
    Dar, Mohd Jamal
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [34] AI-driven discovery and profiling of GTAEXS-617, a selective and highly potent inhibitor of CDK7
    Besnard, Jeremy
    Joseph, James
    Bai, Haiyun
    Paveley, Ross A.
    Wang, Tao
    Barbeau, Olivier R.
    Gu, Xiao-Hui
    Bell, Andrew S.
    Somlyay, Mate
    Taubert, Christina
    Boudesco, Christophe
    Vladimer, Gregory
    Aswad, Fred
    CANCER RESEARCH, 2022, 82 (12)
  • [35] Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation
    Yu, Mingfeng
    Long, Yi
    Yang, Yuchao
    Li, Manjun
    Teo, Theodosia
    Noll, Benjamin
    Philip, Stephen
    Wang, Shudong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 218
  • [36] Discovery of the Potent and Highly Selective PARP7 Inhibitor as a Novel Immunotherapeutic Agent for Tumors
    Gu, Hongfeng
    Yan, Wenxin
    Wang, Yong
    Xu, Wenbo
    Huang, Lei
    Yang, Jieping
    Zhai, Bingxin
    Wang, Hong
    Su, Yupei
    Zhu, Qihua
    Liu, Beibei
    Hao, Haiping
    Zou, Yi
    Xu, Yungen
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (01) : 473 - 490
  • [37] Development of Highly Potent and Selective Pyrazolopyridine Inhibitor of CDK8/19
    Hatcher, John M.
    Vatsan, Prasanna S.
    Wang, Eric
    Jiang, Jie
    Gray, Nathanael S.
    ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (11): : 1689 - 1693
  • [38] Preclinical evaluation of GST-HG161, a potent and highly selective c-MET inhibitor
    Xu, Xiongbin
    Li, Gang
    Hu, Lihong
    Hao, Junguo
    Ding, Charles Z.
    Chen, Shuhui
    CANCER RESEARCH, 2018, 78 (13)
  • [39] Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery
    Liu, Hui
    Liu, Kangdong
    Dong, Zigang
    CANCER RESEARCH, 2021, 81 (01) : 18 - 26
  • [40] Rational discovery of a highly novel and selective mTOR inhibitor
    Jin, Stanley
    Mikami, Satoshi
    Scorah, Nick
    Chen, Young
    Halkowycz, Petro
    Shi, Lihong
    Kahana, Jason
    Vincent, Patrick
    de Jong, Ron
    Atienza, Joy
    Fabrey, Robyn
    Zhang, Lilly
    Lardy, Matthew
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (21)
12345